Affiliation:
1. Colchester General Hospital, UK
2. East Suffolk and North Essex NHS Foundation Trust, UK
Abstract
Aims and Objective: To analyse the outcome of prostatic UroLift (PUL) placement done at our hospital for the treatment of benign prostatic hyperplasia (BPH). Materials and Methods: Demographic and perioperative data were collected for all patients who underwent PUL placement for BPH at out hospital from December 2017 to January 2020. International prostate symptom score (IPSS), quality of life (QoL), maximum urinary flow rate (Q-max), complications and requirement of auxiliary procedures were noted till date. Mann–Whitney U test was used to compare the pre- and post-operative parameters. Results: A total of 45 patients underwent PUL placement and were followed up for a median period of 26 months (range 14–37 months). The median age of the patients and prostate volume were 76 years (range 54–90 years) and 50 mL (range 30–70 mL), respectively. Five patients had median lobe. An average of 3.2 ± 1.1 clips were placed. The mean IPSS, QoL and Q-max in the pre-operative and latest follow-up period were 19.3 ± 5.9 and 11.1 ± 5.6 ( p < 0.001), 4.3 ± 1.1 and 2.5 ± 1.4 ( p < 0.001), 9.8 ± 5.0 mL/s and 12.8 ± 6.2 mL/s ( p = 0.004), respectively. Complications were dysuria (one patient, 2.2%), urinary tract infection (one patient, 2.2%), haematuria (one patient, 2.2%), transient urinary retention (two patients, 4.4%), post-void dribbling (two patients, 4.4%), bladder stone (one patient, 2.2%) and clip migration (one patient 2.2%). Six patients (13.3%) required auxiliary treatment in follow-up. Conclusion: PUL placement improved the IPSS, QoL and Q-max significantly over a median follow-up of 26 months with retreatment rate of 13.3%. It is a safe procedure with few easily manageable complications. Level of evidence: Not applicable